BRISBANE, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.

Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.

Date: Wednesday, May 10, 2017 Time: 1:30 p.m. ET (10:30 a.m. PT)

Dial-in: 1-888-267-6301 Toll/International Dial-in: 1-719-457-2734 Webcast:  http://public.viavid.com/index.php?id=124313

A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.

CONTACT:Investors:Mike ColeO: 949-259-4988C: 949-444-1341mike.cole@mzgroup.usMedia:Lisa GuitermanO: 301-217-9353C: 202-330-3431media@kalobios.com

Primary Logo

If you liked this article you might like

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

Stocks Slip on 2016 Outlook of Middling Economic Growth

Energy Lags Wall Street as Crude Oil Spirals Lower

KaloBios Looks to Restructure While Under Court Protection in Delaware

KaloBios Pharmaceuticals (KBIO) Files For Bankruptcy, Stock Delisted From Nasdaq